Amarin affirms commitment to completion of REDUCE-IT

September 16, 2014 5:11 AM

12 0

Biopharmaceutical Company Amarin Corporation has announced its commitment to complete REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial).

The trial will test the effects on cardiovascular outcomes of Vascepa, which is Amarin's high EPA omega-3 prescription fish oil product, in people with moderately elevated triglyceride levels between 200-499 mg/dL.

Read more

To category page